Cetuximab as a Key Partner in Personalized Targeted Therapy for Metastatic Colorectal Cancer.
Nadia Saoudi GonzálezJavier RosIosune BaraibarFrancesc SalvàMarta Rodríguez-CastellsAdriana AlcarazAriadna GarcíaJosep TaberneroElena ÉlezPublished in: Cancers (2024)
Cetuximab, a chimeric IgG1 monoclonal antibody targeting the epidermal growth factor receptor (EGFR), has revolutionized personalized treatment of metastatic colorectal cancer (mCRC) patients. This review highlights the mechanism of action, characteristics, and optimal indications for cetuximab in mCRC. Cetuximab has emerged as a pivotal partner for novel therapies in specific molecular subgroups, including BRAF V600E, KRAS G12C, and HER2-altered mCRC. Combining cetuximab with immunotherapy and other targeted agents further expands the therapeutic landscape, offering renewed hope for mCRC patients who face the development of resistance to conventional therapies. Ongoing clinical trials have continued to uncover innovative cetuximab-based treatment strategies, promising a brighter future for mCRC patients. This review provides a comprehensive overview of cetuximab's role and its evolving importance in personalized targeted therapy of mCRC patients, offering valuable insights into the evolving landscape of colorectal cancer treatment.
Keyphrases
- metastatic colorectal cancer
- end stage renal disease
- epidermal growth factor receptor
- ejection fraction
- wild type
- clinical trial
- chronic kidney disease
- newly diagnosed
- locally advanced
- small cell lung cancer
- tyrosine kinase
- peritoneal dialysis
- stem cells
- randomized controlled trial
- patient reported outcomes
- radiation therapy
- cell therapy
- hiv infected
- bone marrow
- mesenchymal stem cells
- hiv testing
- open label
- hepatitis c virus